Fig. 3.

SV peptide accelerates the functional recovery of impaired skeletal muscle activities in vivo.

(A) Representative raw electromyography (EMG) traces recorded at 1, 4, and 8 weeks after the masseter muscle injury treated by SV peptide show higher EMG amplitude post-treatment as compared to that treated by PBS [41]. (B) Lissajous figures synthesized from bilateral masseter muscle activities in the VML model recorded 8 weeks after PBS or SV peptide treatment. Each graph presents tracing of the voltage trajectory, with each peak voltage value normalized by the maximum value within 50 bursts recorded from the injected (left) side on the X-axis and the non-injected (right) side on the Y axis. The slope of the fitted line, obtained by regression analysis, shows a significant decrease in the SV peptide group compared with the PBS group [41].